Risk prediction algorithms are widely used for anticoagulation therapy to prevent venous thromboembolism (VTE) during hospitalization [1] [2] [3] . Such algorithms employ several well-known risk factors for hospital-acquired VTE. Less is known regarding the etiology of venous blood clots that form prior to hospitalization for VTE. This is of consequence because there are more than 330,000 hospital admissions for VTE annually in the United States 4 . From 2004-2009, the rate of hospitalization for VTE has increased from 7.0 to 8.4 per 1000 discharges in the United States 4 . Triggers (or potential proximal causes) of such hospitalizations for VTE have not been fully explored although acute-event triggers have been characterized for outcomes such as myocardial infarction, stroke, and drug side effects [5] [6] [7] .
In order to explore triggers that may precipitate hospitalization for VTE, we designed a case-crossover study using the linked databases of the Health and Retirement Study, a longitudinal study of a nationally representative sample of older Americans, and files from the
Centers for Medicare and Medicaid Services (CMS). This design incorporates a within-person
comparison and is particularly useful in evaluating transient exposures while controlling for confounding by fixed covariates such as race and gender, as well as relevant comorbidities and hereditary factors that influence the development of VTE [8] [9] [10] .
Methods

Data Sources
The Health and Retirement Study is an ongoing longitudinal study of Americans 51 years of age and older 11 . Participants were selected from a nationally representative sample of households in the United States and biennial interviews are conducted to collect information regarding economic circumstances, occupations and employment, health and health care, cognition, living by guest on April 14, 2017 http://circ.ahajournals.org/ Downloaded from hospitalization fell within the specific 90-day time period.
Participant characteristics were available in the Health and Retirement Study and included age at the time of VTE hospitalization, gender, race (Caucasian, other), body mass index (BMI, kg/m 2 ) at the time of the first interview, smoking (ever/never with smoking defined as more than 100 cigarettes in a lifetime), and region of residence at the time of the first interview (northeast, midwest, south, west). There were 0.6% (n=3) missing values for BMI and these were imputed prior to analysis. Diagnoses of diabetes, heart disease or cancer were ascertained through questions on the biennial interviews. For example, the participant was asked, "Has a doctor ever told you that you have diabetes or high blood sugar?" Each of these was coded as ever versus never (i.e., no diagnosis at any time).
Statistical Analyses
Characteristics of the participants were initially tabulated both for the sample and, with survey weighting, for the overall fee-for-service Medicare population in the United States. Statistical analyses followed the methods described for case-crossover designs [8] [9] [10] . This study received human subjects approval from the Institutional Review Board at the University of Michigan and the Privacy Board at CMS.
Role of the Funding Source
The National Heart, Lung, and Blood Institute and the National Institute on Aging had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation, review, or approval of the manuscript.
Results
Of the 16,781 participants in the linked database, there were 480 patients who were hospitalized for VTE. Two subjects with VTE hospitalization had fewer than 1.5 years of observation and were excluded as this length of follow-up was necessary to determine exposures in the comparison periods. Of the 478 patients, 79 had a diagnosis of VTE at a date previous to the index hospitalization and therefore were excluded. This yielded 399 patients who were hospitalized for VTE without prior evidence of VTE and were included in the study.
The mean age of the 399 subjects at the time of the hospitalization for VTE was 76.9 years (SD 9.0). There were 4.8% of subjects who were Medicare beneficiaries and were less than 65 years of age when the outcome occurred. Most of the patients hospitalized for VTE were women and Caucasian ( Immobility as defined by any nonsurgical hospitalization or skilled nursing home stay was also a significant trigger of hospitalization for VTE. The risk of VTE hospitalization was 4.2 fold greater in the time period when immobility occurred. Of note, immobility was a relatively common risk factor and occurred in 20.6% of the risk periods just prior to hospitalization for VTE compared to only 6.4% of the comparison risk periods.
We found a strong relationship between erythropoiesis-stimulating agents and hospitalization for VTE, with an adjusted IRR of 9.33 (p=0.034). In this cohort, 3% of the subjects received erythropoiesis-stimulating agents in the 90-day period prior to VTE hospitalization versus 0.8% in the comparison periods. The use of erythropoiesis-stimulating agents was more common in the weeks just prior to hospitalization for VTE (Figure 2 ). Table 2) were included in the regression model. Use of fluorouracil was relatively low, however, with 1.8% of patients exposed in the 90-days prior to the hospitalization for VTE compared to a mean Of the 399 subjects in the study, 69.7% (n=278) had at least one of the following exposures during the 90 days prior to hospitalization for VTE: major surgery, infection, blood transfusion, fracture, nonsurgical immobility, erythropoiesis-stimulating agent, and/or chemotherapy. This was in contrast to 35.3% exposure in the comparison periods, yielding a difference in exposure rates of 34.4% (i.e., "attributable exposure"). These factors, combined, yielded an IRR of 7.04 (95% CI, 5.25, 9.44).
In this cohort, 4.0% of patients died during the hospitalization or were transferred to a hospice after discharge, 20.1% were transferred to a skilled nursing facility or other care facility after discharge, 61.2% went home, and 14.5% were discharged home with services of a home health agency.
Discussion
In this nationally-representative sample of older Americans, infection was the most frequent trigger of hospitalization for VTE, preceding more than half of all such hospitalizations.
Moreover, respiratory tract infection appeared more strongly related to hospitalization for VTE than non-respiratory infections. Infection is not currently included on many clinical VTE risk assessment tools [13] [14] [15] [16] or on patient and consumer-related information sources 17 . Findings from our population-based study are consistent with population-based studies from England and Denmark [18] [19] [20] and with a secondary data analysis of the MEDENOX (prophylaxis in MEDical patients with ENOXaparin) clinical trial 21 . In the Danish study, infection from any source was found to be a strong predictor of VTE, with an elevated VTE risk most predominant within 2 weeks after the onset of infection 18 . In the British investigations, the hypotheses centered on respiratory and urinary tract infections; results from one study indicated that both types of infection predicted VTE 19 while the other found that respiratory tract infections were more strongly related to VTE 20 . The physiological underpinnings of the interconnection between the inflammatory response and coagulation have been well described [22] [23] [24] . Venous stasis is a recognized component of the inflammatory response which enables the migration of leukocytes to the site of infection. Inflammation initiates the tissue factor pathway in the coagulation cascade, through induction of tissue factor by complement activation, endotoxin, C-reactive protein and/or inflammatory cytokines that contribute to hemostasis and thrombus formation 23 .
A patient's ability to resolve an infection while not provoking overstimulation of coagulation would be an important avenue for future research.
Blood transfusion is also not often incorporated in VTE risk prediction tools or patient-education materials [13] [14] [15] [16] [17] . Our finding that blood transfusion precedes VTE hospitalization is consistent with several clinical and laboratory studies. With increased storage, transfused red blood cells have been shown to exhibit greater adhesion to endothelial cells with sequestration in the lungs, resulting in decreased blood oxygenation and exacerbating microvascular pathology 25 .
Hemolysis and microparticle formation occur with increased length of storage and when transfused, is associated with a reduction in vasodilation, platelet adhesion and aggregation, and exacerbation of inflammation 26 . Unfortunately, length of storage was not available in our database for red cell transfusion nor was there information regarding the quantity of transfused red cells, platelets or plasma. However, both red blood cell and platelet transfusions were found to be risk factors for VTE in a study of 504,208 hospitalizations using the University Health System Consortium data 27 . Blood transfusion was also a significant predictor of VTE in a study of 21,943 patients undergoing colorectal resection using data from the National Surgical Quality Improvement Program 28 . Clinical trials comparing different transfusion thresholds have been too small to evaluate VTE risk (2 trials with a total of 204 patients) 29 .
A potent trigger of hospitalization for VTE is the use of erythropoiesis-stimulating agents. A meta-analysis of Phase 3 trials of erythropoiesis-stimulating agents in patients with cancer demonstrated an increased risk of VTE and mortality 30 . There have been several trials suggesting concerns with administration in patients with chronic kidney disease as well 31 .
Labeling of these drugs was revised by the FDA with a black box warning in 2007 for treatment in patients with cancer and in 2011, the FDA issued a safety communication regarding their use in patients with chronic kidney disease 32, 33 . Nevertheless, one of the erythropoiesis-stimulating agents was still among the top 10 prescribed drugs in the United States in 2010 based on sales 34 .
Furthermore, there is considerable variability in use across providers 35 . Unfortunately, our findings suggest that patients who receive either erythropoiesis-stimulating agents or blood transfusions, two of the most common therapies available for anemia management, are at markedly higher risk of VTE.
Antipsychotic medications were found to increase the risk of VTE in a large primary care population-based study in the United Kingdom 36 . In their results, the adjusted odds ratio for VTE was most elevated for antipsychotics given by injection (odds ratio, 3.24). Since injectable medications were available through Medicare data in our study, we evaluated injectable antipsychotics as well. The adjusted IRR was not significant in our study, although utilization of antipsychotic medications was rather low (1.0% in the risk period and 0.3% in the comparison periods) and therefore, it is possible that we did not have sufficient power to detect such differences.
Our findings that established risk factors of VTE are triggers of hospitalization for VTE (e.g., surgery, fractures, immobility, chemotherapy) indicate that this particular study design is suitable for evaluating such predictors. Moreover, the case-crossover design implicitly controls for genetic determinants, demographic characteristics and past comorbidities since the comparisons are made within the individual. Therefore, the findings are not due to differences in the genetic profile of patients or medical history of various chronic conditions; such factors are fixed in this study.
There are some limitations of this study. First, we would have preferred a larger database in order to investigate less common exposures, particularly since exposure occurrence was within specific time ranges. Second, oral medications were not available in the existing database so we were unable to evaluate hormone replacement therapy or other medications that may trigger or prevent VTE. Likewise, we were unable to completely characterize immobility in this database. It is possible that there were other factors that changed between the risk period and the comparison periods. There was a maximum of 1.5 years from the beginning of the first comparison period and the end of the risk period. Therefore, changes in factors related to vascular health could have occurred that were not recorded in the medical visits and stays available through the hospital, skilled nursing home, home health, physician, or outpatient files.
Moreover, interviews in the Health and Retirement Study occurred every two years and therefore, changes in habits within shorter periods of time (e.g., 6 months) were not known.
While we considered the possibility of diagnostic bias (e.g., VTE found during a diagnostic work-up for infection), the date of the visit/stay when the infection was recorded was prior to the date of hospitalization for VTE. Moreover, at the time when the infection was recorded (either during a clinic visit, home health visit, previous hospital stay, etc), VTE was not recorded. This provides evidence that the infection occurred prior to the VTE.
In conclusion, infection is a common potential trigger of hospitalization for VTE and patients should be made aware of this risk. Exposure to erythropoiesis-stimulating agents and blood transfusion are not as common but, if administered, these therapies confer significantly elevated risk of hospitalization for VTE. Current risk algorithms for VTE need reassessment and possible updating to include infection, erythropoiesis-stimulating agents and blood transfusion.
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